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Abstract
Background: The relationship between menopausal hormone therapy (MHT) and cardiovascular risk remains controversial,
with a number of studies advocating the use of MHT in reducing risk of cardiovascular diseases, while others have shown it
to increase risk. The aim of this study was to determine the association between menopausal hormone therapy and high
blood pressure.
Methods and Findings: A total of 43,405 postmenopausal women were included in the study. Baseline data for these
women were sourced from the 45 and Up Study, Australia, a large scale study of healthy ageing. These women reported
being postmenopausal, having an intact uterus, and had not been diagnosed with high blood pressure prior to menopause.
Odds ratios for the association between MHT use and having high blood pressure were estimated using logistic regression,
stratified by age (,56 years, 56–61 years, 62–70 years and over 71 years) and adjusted for demographic and lifestyle
factors. MHT use was associated with higher odds of having high blood pressure: past menopausal hormone therapy use:
,56 years (adjusted odds ratio 1.59, 99% confidence interval 1.15 to 2.20); 56–61 years (1.58, 1.31 to 1.90); 62–70 years
(1.26, 1.10 to 1.44). Increased duration of hormone use was associated with higher odds of having high blood pressure, with
the effect of hormone therapy use diminishing with increasing age.
Conclusions: Menopausal hormone therapy use is associated with significantly higher odds of having high blood pressure,
and the odds increase with increased duration of use. High blood pressure should be conveyed as a health risk for people
considering MHT use.
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Introduction
Menopausal hormone therapy (MHT) is primarily prescribed
for the treatment of perimenopausal symptoms. A common
concern among those who manage menopausal women is the risk
of unfavourable effects of menopausal hormonal therapy on long-
term health, particularly cardiovascular health. Early observation-
al studies have shown a reduced incidence of coronary heart
disease in women receiving MHT, which suggested MHT
protected against coronary heart disease. [1] Clinical trials later
suggested MHT did not reduce the risk of coronary heart disease
and was of no benefit to cardiac health. [2] Re-examination of trial
data has since shown a possible reduced risk of coronary heart
disease after 6 years of treatment. [3] As a result, there is still much
confusion over the effect of MHT on cardiac health.
Hypertension, or high blood pressure, is considered a major risk
factor for cardiovascular morbidity and mortality in postmeno-
pausal women. A number of environmental and genetic factor are
associated with risk of developing high blood pressure, with
increasing age the largest contributor. [4] Studies investigating the
relationship between MHT and blood pressure have also been
largely inconsistent. Baseline data from the observational arm of
the WHI found current MHT use was associated with an
increased likelihood of hypertension. [5] Various clinical trials in
normotensive women have either reported no difference in blood
pressure with MHT, [6] a decrease in blood pressure with MHT
use, [7] or a slight increase in blood pressure with MHT use, [2]
compared with placebo. Similarly, studies in hypertensive
postmenopausal women have either shown a slight decrease in
blood pressure with MHT use, [8] or no effect on blood pressure
with MHT use. [9].
Our study investigated the relationship between the use of
MHT and prevalence of high blood pressure, in Australian
postmenopausal women aged 45 years and over, the 45 and Up
Study. The aim of this current study was to ascertain the association
between MHT use and high blood pressure, and whether the
number of years spent taking MHT is associated with having high
blood pressure.
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Results
A total of 43,405 women were included in the study (Fig. 1).
These women were postmenopausal, had reported to having an
intact uterus, had gone through menopause, had not started MHT
treatment prior to menopause, and had not been diagnosed with
high blood pressure prior to menopause. Of the 12,443 women
who had used MHT (past or current), 2,536 (20%) reported
having high blood pressure compared to 5,149 (17%) of the 30,962
women who had never used MHT.
Demographic and lifestyle characteristics of MHT users,
compared to women who have never used MHT are outlined in
Table 1. Women with a family history of high blood pressure were
more likely to use MHT than women without a family history of
high blood pressure. MHT use was significantly more common in
women who reported sufficient levels of physical activity, who
were past smokers, who reported drinking alcohol, and who had a
history of oral contraceptive use. Women who were obese (BMI
greater 30), were current smokers, and had given birth were less
likely to use MHT compared with women of a healthy BMI,
women who had never smoked, and women who had never given
Figure 1. Participants included in the study.
doi:10.1371/journal.pone.0040260.g001
Hormone Therapy Is Associated with High BP
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e40260
birth, respectively. Country of origin and income were not
significantly associated with MHT use.
The average age for women who had ever used MHT was
63.5 years and 63.7 years for women who had never used MHT
(b= 0.14, 99% confidence interval 20.14 to 0.42; p = 0.21). In
younger women (,56 years and 56–61 years), analysis looking at
current MHT exposure found a significantly higher odds for
having high blood pressure in both current and past users of
MHT, when compared to women who had never used MHT
(Figure 2). In women aged between 62–70 years, there were
significantly higher odds of having high blood pressure in past
users of MHT compared to women who had never used MHT
(Figure 2). In older women (+71 years), there was no association
between MHT use and having high blood pressure (Figure 2).
There was no significant difference in odds for having high blood
pressure between past and current users of MHT in any age
group, and as a result, subsequent analysis combined both past
and current users of MHT.
The average age at menopause was 48.2 years for women who
had ever used MHT and 49.8 years in women who had never
used MHT (b= 1.53, 1.41 to 1.66; p,0.001). The average age for
when women initiated MHT treatment was 51.6 years. The
average age when high blood pressure was first diagnosed was
58.5 years in women who had ever used MHT and 61.3 years in
women who had never used MHT (b= 2.8, 2.20 to 3.36;
p,0.001).
Duration of MHT use was associated with an overall increase in
odds for having high blood pressure, with women who had used
MHT for longer time periods having increased odds for having
high blood pressure (Figure 3). However, the effect of duration of
MHT use on odds for having high blood pressure was less evident
as women got older.
Within a subgroup of MHT users only, no significant
association between when MHT was initiated relative to
menopause and having high blood pressure was observed at any
age group. Additionally, in women who had been treated with
MHT in the past, no association between length of time since
MHT exposure ceased and having high blood pressure was
observed.
Discussion
This study found that postmenopausal women who use MHT
had higher odds of having high blood pressure, and that the longer
a woman uses MHT the higher her odds for having high blood
pressure, irrespective of both when MHT was initiated relative to
menopause and the number of years since stopping treatment.
Additionally, women who had ever used MHT were first
diagnosed with high blood pressure 2.8 years earlier than women
Table 1. Socio-demographic factors and health risk factors associated with MHT use.
Characteristics N (% column) % MHT Odds ratio (99% CI){
Country of origin Australia 32 360 (75) 29 1.00
Other 10 680 (25) 28 1.06 (0.99 to 1.13)
Income ,$30K 13 319 (30) 28 1.00
$30K – $70K 10 908 (25) 31 1.10 (1.01 to 1.19){
$70K+ 8 460 (19) 28 0.92 (0.84 to 1.00)
Did not disclose 10 718 (25) 28 1.01 (0.94 to 1.09)
Family history of HBP No 21 882 (50) 28 1.00
Yes 21 523 (50) 30 1.17 (1.05–1.18){
BMI ,25 19 905 (46) 29 1.00
25–30 13 069 (30) 30 1.02 (0.96 to 1.09)
30+ 7 063 (16) 27 0.91 (0.83 to 0.99){
Smoking status Never 28 276 (65) 27 1.00
Past 12 094 (28) 33 1.14 (1.07 to 1.21){
Current 2 840 (7) 27 0.82 (0.73 to 0.93){
Alcohol (drinks/week) 0 16 994 (39) 25 1.00
1–5 11 461 (26) 30 1.23 (1.14 to 1.32){
6–10 8 467 (20) 32 1.30 (1.20 to 1.41){
11+ 5 517 (13) 34 1.36 (1.24 to 1.49){
Physical activity Insufficient 13 028 (30) 26 1.00
Sufficient 30 377 (70) 30 1.18 (1.11 to 1.26){
Past oral contraceptive use No 10 377 (24) 17 1.00
Yes 32 692 (75) 32 2.73 (2.51 to 2.97){
Have you ever given birth? No 5 197 (12) 30 1.00
Yes 37 954 (87) 29 0.91 (0.83 to 0.99){
% MHT – the percentage of women who responded yes to having ever used MHT. Percentages do not consistently total to 100% due to missing values.
{Adjusted for age, country of origin, income level, BMI, smoking status, alcohol consumption, physical activity, family history of high blood pressure, history of oral
contraceptive use, age at menopause, and whether a woman had given birth.
{p,0.01.
doi:10.1371/journal.pone.0040260.t001
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who had never used MHT and as the age of women increased, the
association between MHT use and high blood pressure dimin-
ished. The association between the duration of MHT use and high
blood pressure also diminished with increased age, demonstrating
age as a significant predictor for the development of high blood
pressure. [10].
Strengths and Limitations of the study
The key strength of our study was the large sample size, which
enabled us to test whether MHT use and duration of MHT use
was associated with high blood pressure. It confirms cross-sectional
baseline results from the WHI, [5] and extends these findings by
showing that both past and current users of MHT have higher
odds of having high blood pressure, and that the association
between MHT use and high blood pressure is higher in younger,
postmenopausal women. Furthermore, this is the first report that
the longer a woman uses MHT the higher her odds for having
high blood pressure, and is retained irrespective of when MHT
was initiated relative to menopause, or the number of years since
ceasing MHT treatment.
A limitation of the study was that it analysed cross-sectional
baseline data from the 45 and Up Study and, as a result, the casual
nature of associations could not be assessed. Additionally, while
several known risk factors for high blood pressure were statistically
controlled for, factors known to be associated with altering a
woman’s risk of having a cardiovascular disease, including the type
and dosage of MHT, could not be determined. A further
limitation is the study’s reliance on self-reported data. This
method is prone to potential recall bias, which may lead to under-
reporting or over-reporting of age at diagnosis, and menopause
status. Bias and over-estimation of effects may have potentially
been introduced as women who use MHT will have routine health
checks and may be more likely to be diagnosed with high blood
pressure. However, research has shown that women who use
MHT represent a healthier subgroup of the female population,
[11] and supports our data, which shows women who use MHT
are more likely to be of a healthy weight and be physically active.
Comparison with other studies
The relationship between MHT use and blood pressure has
been inconsistently reported in the literature. Studies in healthy
postmenopausal women have found either no treatment related
changes in blood pressure, [6] or a lowering of blood pressure. [7]
A study looking at hypertensive postmenopausal women, treated
with low doses of oral MHT over a 12 month period, also
observed a significant decrease in blood pressure in the MHT
group. [8] Baseline data from the observational arm of the WHI
showed that current HRT use was associated with a 25%
Figure 2. The odds for having high blood pressure in women who have ever used MHT compared with women who have never
used MHT, stratified by current age.
doi:10.1371/journal.pone.0040260.g002
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increased likelihood of hypertension, after adjusting for known
confounders. [5] Increases in systolic blood pressure with MHT
use were also observed in the estrogen plus progestin component
of the WHI, [2] and the estrogen only component of the WHI.
[12] These studies focused on changes in blood pressure while the
women were actively receiving MHT treatment. Our results
support the conclusions drawn from the WHI observational
baseline study and are consistent with the larger clinical trials,
which suggest that current MHT use influences blood pressure.
Additionally, our data showed that past MHT use is associated
with higher odds of having high blood pressure, and these odds
remain regardless of the length of time since last exposure.
The timing of initiation of MHT relative to menopause may
influence its effect on cardiovascular disease, with secondary
analysis of WHI data observing a trend for reduced CHD in
younger women who initiated MHT closer to when menopause
began. [3] In our study, no association between the when MHT
was initiated relative to the onset of menopause was seen. Whether
the initiation of MHT prior to the onset of menopause is beneficial
to cardiac health, is currently being investigated in the Kronos
Study. [13] Our study only included women who had initiated
MHT after menopause, as women who initiate MHT prior to
menopause are unable to ascertain their menopause status.
Vasomotor symptoms, such as hot flushes, are the primary
reason women seek MHT treatment. [14] Women with and
without hot flushes have different vascular responses to MHT. [15]
This may explain the different results between studies. The
severity of hot flushes have been shown to be an independent
predictor of endothelial dysfunction, [16] and have been suggested
as a marker of cardiovascular risk. [17] It may be women who
require MHT to treat vasomotor symptoms are at an increased
risk of cardiovascular disease and high blood pressure, irrespective
of whether they use MHT. Alternatively, exposure to MHT may
further exacerbate existing endothelial damage, which results in
high blood pressure even after treatment has stopped. Our data
found no significant difference in odds of having high blood
pressure between current and past users, with increased odds
observed for both groups, compared to women who had never
used MHT. Additionally, the number of years since women were
last exposed to MHT was not significantly associated with having
high blood pressure, that is, the odds of having high blood pressure
remains the same, whether you ceased treatment one year ago or
more than a decade ago.
Implications and future research
Women should be prescribed MHT for as short a time as
possible and their cardiovascular health, specifically blood
pressure, should be closely monitored both during and after
therapy. How endothelial dysfunction is associated with meno-
pausal symptoms and the effect of MHT on the vascular system
remains to be investigated. A clinical trial of MHT, which includes
an extended period of follow up after cessation of treatment, is
Figure 3. The odds of having high blood pressure depending on duration of MHT use compared to women who have never used
MHT, stratified by current age.
doi:10.1371/journal.pone.0040260.g003
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required to decipher how MHT treatment leads to higher odds of
having high blood pressure. Such a trial should initiate MHT close
to menopause and only include women who have never used
MHT previously.
Conclusions
Menopausal hormone therapy use is associated with higher odds
of having high blood pressure particularly in younger postmen-
opausal women. Increased duration of menopausal hormone
therapy use is also associated with higher odds of having high
blood pressure, and this persists regardless of the time since MHT
was initiated after menopause, or the length of time since a women
stopped using MHT. Our results align with the current Food and
Drug Administration recommendations, [18] that MHT treatment
be limited to the shortest possible duration consistent with
treatment goals. Women who require MHT should be closely
monitored as they may represent a population of women with
subclinical cardiovascular disease, and blood pressure should be
regularly monitored even after treatment ceases. Furthermore,
high blood pressure should be conveyed as a health risk for people
considering MHT use.
Methods
Data was obtained from women who were recruited from the 45
and Up Study. The methods for the 45 and Up Study have been
described elsewhere. [19] Briefly, the 45 and Up Study is a large
scale cohort study of healthy ageing that involves 266,848 men and
women aged 45 years and over from the general population of
New South Wales, Australia. Individuals were sampled from the
Medicare Australia database. Study recruitment commenced in
2006 and was completed in 2009. The 45 and Up Study received
ethics approval from the University of NSW Human Ethics
Committee. Although derived from the general population, the
relatively low response rate means that the cohort is unlikely to be
directly representative of the general population. [19] However,
exposure-outcome relationships estimated from the 45 and Up Study
data have been shown to be consistent with another large study of
the same population, regardless of the underlying response rate or
mode of questionnaire administration. [20].
All of the variables used in this study were derived from self
reported data obtained from the 45 and Up Study baseline
questionnaire (available at www.45andUp.org.au). Only data from
female participants was included in this study. Only women who
responded ‘‘No’’ to having had a hysterectomy or both ovaries
removed were included. Only women who responded ‘‘Yes’’ to
‘‘Have you been through menopause?’’ and provided an age that
menopause began were included. Women who responded ‘‘No’’,
‘‘Not sure (because hysterectomy, taking HRT, etc.)’’ or ‘‘My periods
have become irregular’’ were not included in the study. Women
were classified as having ever had high blood pressure according to
their response to the question ‘‘In the last month have you been
treated for high blood pressure?’’. Only women who did not report
having high blood pressure prior to menopause were included.
Women who answered ‘‘Yes’’ to ‘‘Has a doctor ever told you that
you have: high blood pressure – when not pregnant’’, but were not
being treated for high blood pressure, were excluded. Women who
reported menopause before the age of 30 years were excluded.
Women who reported current oral contraceptives use were
excluded. Variables were classified according to the groups in
Table 1.
For ‘Country of birth’, participants were classified according to
whether they had been born in Australia or born in a country
other than Australia. Physical activity levels were assessed using
questions from the Active Australia Survey. Vigorous activity
received twice the weighting of moderate or walking activity, [21]
and individuals were categorised into sufficient (.150 minutes per
week) or insufficient levels. [22].
Regarding use of MHT, women were asked ‘‘Have you ever
used hormone replacement therapy?’’ and ‘‘If Yes, for how long
altogether have you used hormone replacement therapy?’’ (in
years). Women were also asked ‘‘Are you currently taking
hormone replacement therapy?’’ and ‘‘If No, at what age did
you stop?’’. MHT use was analysed as a dichotomous variable
(ever used MHT/never used MHT), and categorical current
MHT exposure (never used MHT, past use, and current use), with
women who had never used MHT as the reference group.
Duration of MHT use in years was analysed as a categorical
variable, divided into quartiles (never; ,2 years; 2–4 years; 5–
9 years; and 10 or more years), with women who had never used
MHT as the reference group. Women with missing data for these
variables were excluded.
For women who had used MHT in the past, the age that these
women began MHT treatment was calculated by subtracting the
number of years that they had used MHT from the age that these
women stopped taking MHT. For women currently using MHT,
the number of years that they had been using MHT was
subtracted from their current age. The age that menopause
occurred was then subtracted from the age that MHT use began,
to calculate the length of time between when MHT use began
relative to menopause. Women who began using MHT prior to
menopause were excluded. The length of time since MHT
treatment was stopped was calculated for women who had used
MHT in the past, by subtracting the woman’s current age from
the age that MHT was stopped.
Odds ratios and 99% confidence intervals were estimated using
logistic regression. Both crude and adjusted odds ratios were
calculated and descriptions refer to adjusted odds ratios unless
otherwise specified. Odds ratios were adjusted for demographic
and lifestyle factors using the categories in Table 1, with an
additional category for missing values. Tests for interactions
between covariates and MHT use, with odds for high blood
pressure were performed. A significant interaction between age
and MHT use with having high blood pressure was observed. As a
result, women were stratified according to age and divided into
quartiles (,56 years, 56–61 years, 62–70 years and 71 years or
older). Odds ratios were calculated for each age group. No other
significant interactions were observed. All statistical tests were two-
sided, using a significance level of p,0.01 to partially account for
multiple testing issues. [3,23,24] Conclusions were drawn based on
both significance and the effect size.
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